Clinical Data Fraud Involving CROs Attracting US Justice Department Attention
Executive Summary
Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.
You may also be interested in...
Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems
Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.
Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems
Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.
Data Integrity Fallout: Sponsors Risk Reputational Damage, Negative Impacts On Other Research
US is going after fraudulent clinical trial conduct, and sponsors may be faced with determining the breadth of such fraud, whether studies will be delayed and impacts on other development programs; how a sponsor handles potential fraud could define their future interactions with FDA, DoJ.